A large language model-based AI system deployed at Cleveland Clinic effectively identified diverse, eligible participants for a rare disease clinical trial through EMR screening.
Key Details
- 1Cleveland Clinic and Dyania Health used an AI system (Synapsis AI) to pre-screen for a Phase 3 trial in transthyretin amyloid cardiomyopathy (ATTR-CM).
- 2In one week, the AI reviewed 1,476 records and identified 46 potential matches; 29/30 AI-identified matches were missed by traditional methods.
- 3The AI achieved 96.2% accuracy for 7,700 trial-specific questions and a 99% negative predictive value (NPV) in excluding ineligible patients.
- 4AI-assisted recruitment led to a more diverse patient cohort, with 36.6% Black participants versus 7.1% via routine screening.
- 5Only 60% of AI-identified patients had heart failure specialist care, versus 92.8% found by traditional methods, showing improved outreach.
- 6The system used both structured EMR data and NLP to analyze clinical notes and provided auditable inclusion/exclusion justifications.
Why It Matters
This study showcases the potential of AI-driven EMR review to increase trial enrollment efficiency and address disparities by identifying qualified participants who might otherwise be overlooked, particularly in underrepresented groups. It underlines how imaging and clinical AI advancements are intersecting with research recruitment and population health strategies.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
•EurekAlert
AI Model Accelerates Accurate Dose Prediction for CyberKnife Radiotherapy
A physics- and spatially informed diffusion model accelerates Monte Carlo–level dose estimation for CyberKnife radiotherapy using planning CT and anatomical data.